How could the development of new chronic cough indications affect the Center for Drug Evaluation and Research?
CDER's review workload increases as drug seeks approval for new chronic cough indications The company developing Haduvio is advancing clinical programs for severe refractory chronic cough (RCC) and non-IPF-ILD chronic cough. These trials, including the LAKE Phase IIb trial for RCC and a Phase II dose-ranging study for non-IPF-ILD, are designed to support future regulatory submissions to the FDA. As CDER is the division responsible for the scientific review of drug applications, the pursuit of these new indications requires CDER to dedicate resources to evaluating the efficacy and safety data for these specific chronic cough treatments.
- Effect
- Mixed
- How direct
- 3 steps, 1 inferred by Brind
- When
- Within months
- The story
- No new developments lately
How it reaches Center for Drug Evaluation and Research
-
As of September 30, 2026, the company reported $299.4 million in cash and marketable securities, up from $188.3 million at the end of 2025. The company stated its current cash runway is sufficient to fund lead clinical programs through potential FDA approval. Research and Development Expenses increased to $19.1 million, primarily due to costs for the OCEAN-1, OCEAN-2, and LAKE clinical trials.
The full event1independent outlet -
The company is funding clinical programs for Haduvio, including the LAKE Phase IIb trial for refractory chronic cough (RCC) and a Phase II dose-ranging study for non-IPF-ILD chronic cough. These studies are designed to gather data necessary for future regulatory submissions.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- aol.com Tuesday
-
legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective
Everything about company -
The company has aligned with the FDA on the development plan for non-IPF-ILD-related chronic cough, and management reports the FDA is supportive of getting the first chronic cough drug approved in the U.S. This alignment sets the stage for formal regulatory review.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- aol.com Tuesday
-
As the Center for Drug Evaluation and Research is the formal division of the FDA responsible for the scientific review and approval of new drug indications, the company's pursuit of approval for RCC and non-IPF-ILD chronic cough necessitates CDER's specialized evaluation of the clinical data.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
FDA research center
Everything about Center for Drug Evaluation and Research
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The company is running the LAKE Phase IIb trial for refractory chronic cough (RCC).aol.com
- A Phase II dose-ranging study is planned for non-IPF-ILD chronic cough, targeting approximately 120 patients.aol.com
- The company aligned with the FDA on the development plan for non-IPF-ILD-related chronic cough in October.aol.com
- The FDA pulmonary division discussions have been collaborative and clear regarding the first chronic cough drug approval.aol.com
Why it matters
For the company, the successful navigation of these clinical programs and the FDA's support for the chronic cough indications are critical to establishing a new market for Haduvio. The non-IPF-ILD market, for example, is noted to more than double the IPF potential, making the successful regulatory approval of these new indications a major commercial opportunity.
For the Center for Drug Evaluation and Research, the influx of complex, novel drug applications for chronic cough conditions increases its operational focus. CDER must dedicate its scientific expertise to evaluating the heterogeneity of patients and the efficacy of new mechanisms of action, such as the dual mechanism of nalbuphine, to determine if the drug meets the standards for approval.
What we don't know yet
- What specific data points from the LAKE Phase IIb trial will determine the next steps for RCC?
- How will CDER prioritize the review of these new chronic cough indications against other drug applications?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- MerckPossibleNew chronic cough drug may increase competition for Merck
- CongressPossibleFDA's support for new chronic cough drugs may influence future regulatory mandates
- Drug Enforcement AdministrationPossibleNew nalbuphine formulation may require DEA oversight for chronic cough
- Eli Lilly and CompanyPossibleNew chronic cough drug may increase competition for Eli Lilly
- United States of AmericaPossibleNew chronic cough drug approval could set new standards for US patient care.
Reporting
- aol.comTuesday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.